论文部分内容阅读
目的 评价膦甲酸钠与干扰素α序贯抗乙肝病毒的临床疗效。方法 选择慢性乙型肝炎 40例 ,随机分为两组 ,治疗组 15例。第一阶段治疗在基础护肝治疗基础上应用膦甲酸钠 3 0 g加入 10 %葡萄糖 5 0 0mL2h内滴完 ,每日 1次 ,疗程 30d ;之后用干扰素α 5 0 0U ,每日 1次 ,肌注 2 0d后改隔日 1次肌注 ,疗程 6个月。对照组 2 5例 ,第一阶段治疗采用基础护肝治疗 ,待ALT在正常值上限 2～ 3倍升高 ,无黄疸时给予干扰素α ,剂量及方法、疗程同序贯治疗组。结果 第一阶段治疗 ,治疗组有 2例轻度恶心 ,食欲不振 ,停药后消失。肝功能好转治疗组平均 18d ,对照组平均 2 7d ,明显优于对照组 (P <0 0 5 )。治疗组显效 6例 ,6 / 15 ,优于对照组 7例 ,7/ 2 5 (P <0 0 5 )。HBV标志物下降数值优于对照组。结论 膦甲酸钠与干扰素α序贯用于抗乙肝病毒疗效肯定 ,病毒指标转阴快。
Objective To evaluate the clinical efficacy of foscarnet and interferon α against hepatitis B virus. Methods Forty patients with chronic hepatitis B were randomly divided into two groups, the treatment group of 15 cases. The first phase of treatment based on the treatment of liver protection based on the application of foscarnet 30 g added 10% glucose 500 ml 2h drip End, once daily for 30 days; followed by interferon α 5 0U, 1 times a day, Intramuscular injection 2d after another intramuscular injection, treatment for 6 months. The control group 25 cases, the first phase of treatment based on the treatment of liver, ALT to be the upper limit of normal 2 to 3 times higher, without jaundice given interferon α, dose and method, the same treatment with the treatment group. Results The first phase of treatment, the treatment group had 2 cases of mild nausea, loss of appetite, disappeared after stopping. The improvement of liver function in the treatment group averaged 18 days, the control group averaged 27 days, which was significantly better than the control group (P <0 05). The treatment group was significantly improved in 6 cases, 6/15, better than the control group in 7 cases, 7/2 5 (P <0 05). HBV markers decreased better than the control group. Conclusion The sequential use of foscarnet and interferon α for the treatment of hepatitis B virus has a certain effect, and the viral index turns negative fast.